CEACAM5 and familial pancreatic carcinoma: The pancreatic cancer patient received 109-5 × 1010 retroviral transduced CEA CAR T cells i.v. and seven doses IL-2 with cyclophosphamide and fludarabine preconditioning. All patients had adverse events with grade ≤ 2 and lack of prolonged CAR T cell persistence led to the premature termination of the trial. No objective clinical response observed although serum CEA level reduced in the pancreatic cancer patient (47).